Brain scans could guide depression treatment in new stanford trial

NCT ID NCT07022405

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Stanford University is studying whether the drug pramipexole can help people with depression, and if its effects depend on specific brain circuits. Sixty adults with recent depressive symptoms will take pramipexole for 8 weeks, then taper off over 2 weeks. The study uses brain imaging and questionnaires to see how the drug affects mood, behavior, and thinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pramipexole immediate release
What this could lead to: If successful, this could point toward a more personalized way to treat depression by matching medications to a person's specific brain circuit activity.
What could go wrong: This is a small Phase 2 study (60 people) without a placebo group, so results may not apply broadly. Pramipexole can cause side effects like nausea, dizziness, and impulse control issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Stanford University
RECRUITING

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.